Bronfman E.L. Rothschild L.P. increased its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 21.1% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,652 shares of the biotechnology company’s stock after purchasing an additional 1,505 shares during the quarter. Bronfman E.L. Rothschild L.P.’s holdings in BioMarin Pharmaceutical were worth $839,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in BMRN. Huntington National Bank purchased a new position in shares of BioMarin Pharmaceutical in the 3rd quarter valued at about $105,000. BDO Wealth Advisors LLC acquired a new stake in BioMarin Pharmaceutical in the 2nd quarter valued at about $127,000. NuWave Investment Management LLC grew its stake in BioMarin Pharmaceutical by 42,975.0% in the 3rd quarter. NuWave Investment Management LLC now owns 1,723 shares of the biotechnology company’s stock valued at $167,000 after acquiring an additional 1,719 shares during the last quarter. Meiji Yasuda Asset Management Co Ltd. acquired a new stake in BioMarin Pharmaceutical in the 3rd quarter valued at about $204,000. Finally, Motley Fool Asset Management LLC acquired a new stake in BioMarin Pharmaceutical in the 3rd quarter valued at about $217,000.

In other BioMarin Pharmaceutical news, EVP George Eric Davis sold 12,000 shares of the firm’s stock in a transaction dated Thursday, September 13th. The shares were sold at an average price of $99.57, for a total transaction of $1,194,840.00. Following the sale, the executive vice president now directly owns 74,950 shares of the company’s stock, valued at approximately $7,462,771.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director V Bryan Lawlis sold 2,150 shares of the firm’s stock in a transaction dated Thursday, September 27th. The stock was sold at an average price of $97.93, for a total transaction of $210,549.50. Following the sale, the director now directly owns 21,310 shares in the company, valued at $2,086,888.30. The disclosure for this sale can be found here. Insiders have sold a total of 32,650 shares of company stock worth $3,150,680 over the last ninety days. 1.90% of the stock is owned by corporate insiders.

A number of brokerages recently commented on BMRN. BidaskClub raised shares of BioMarin Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Tuesday, October 9th. Citigroup increased their price objective on shares of BioMarin Pharmaceutical from $108.00 to $120.00 and gave the company a “buy” rating in a research note on Thursday, August 9th. Cantor Fitzgerald set a $126.00 price objective on shares of BioMarin Pharmaceutical and gave the company a “buy” rating in a research note on Sunday, October 7th. Zacks Investment Research cut shares of BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Friday, October 5th. Finally, ValuEngine cut shares of BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Saturday, September 1st. One analyst has rated the stock with a sell rating, four have given a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the stock. BioMarin Pharmaceutical has an average rating of “Buy” and an average target price of $117.00.

BioMarin Pharmaceutical stock opened at $93.69 on Thursday. BioMarin Pharmaceutical Inc. has a 12-month low of $75.81 and a 12-month high of $106.74. The company has a current ratio of 2.87, a quick ratio of 2.26 and a debt-to-equity ratio of 0.28.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings results on Thursday, October 25th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.22) by $0.15. BioMarin Pharmaceutical had a negative net margin of 8.35% and a negative return on equity of 2.98%. The company had revenue of $391.71 million for the quarter, compared to analysts’ expectations of $369.43 million. Equities analysts expect that BioMarin Pharmaceutical Inc. will post -0.14 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.watchlistnews.com/biomarin-pharmaceutical-inc-bmrn-shares-bought-by-bronfman-e-l-rothschild-l-p/2664091.html.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical, Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome.

Further Reading: Short Selling – Explanation For Shorting Stocks

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN).

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.